Skip to main content
  1. Home
  2. Promotions
  3. GenetiSure Dx Postnatal Assay Parents & Counselors

GenetiSure Dx Postnatal Assay Parents & Counselors

GenetiSure DX banner

Our Focus: Improving Quality of Life

Genetic defects can be responsible for a wide range of disorders, from intellectual disability to congenital dysmorphisms, neuromuscular disorders, epilepsy and autism.

In addition, genetic defects can be responsible for Developmental Delay (DD) and Intellectual Disability (ID), including Autism Spectrum Disorder (ASD) and Attention Deficit Hyperactivity Disorder (ADHD).

Many of these are copy-number variants, deleted or duplicated regions of the genome that can range in size from very small to entire chromosomes.

Although the average age of diagnosis for pervasive developmental disorder can be as late as four years old, research has shown that an early diagnosis can be critical2 to the prognosis of the child, as it can enable interventions that may prevent, anticipate or more successfully treat complications.3 Diagnosis can also facilitate financial support, educational assistance and membership in support groups.

The GenetiSure Dx Postnatal Assay 

The GenetiSure Dx Postnatal Assay uses Agilent proprietary aCGH for copy-number and LOH data, enabling cytogeneticists to accurately detect genetic anomalies associated with developmental delay, intellectual disability, congenital anomalies, and dysmorphic features in children and adults.

Copy number changes are the causes of about 25% to 30% of all major congenital dysmorphisms1

Genetic anomalies account for 25% to 50% of ID cases, and this number increases with the severity of the disability

Median global prevalence of ASD alone was an estimated 62/10,000 in 2012

At least 10% of all neonatal intensive-care unit admissions involve the presence of congenital dysmorphisms2
 

What is aCGH and why?

Comparative Genomic Hybridization Arrays (aCGH) use a modified in situ hybridization technology, that allows detection and mapping of gDNA sequence copy differences between two genomes in a single experiment.

Analysis of fluorescence intensity of probes with respect to their genomic location enables detection of regions where copy-number variations (CNVs) and copy-neutral loss of heterozygosity (cnLOH) may occur.

Figure: aCGH uses a two-color fluorophore hybridization that provides an easy visual identification and comparison of gains and deletions in the genome leading to copy number variation, between the test and reference samples. The results obtained with FISH offer less resolution and quantitative comparison between test and reference samples.

Higher diagnostic yield, increased resolution and greater sensitivity make aCGH a superior method compared with traditional karyotyping or FISH. Medical geneticists now consider aCGH to be the standard test for detecting CNVs linked to a unique patient or to one of the many known genetic disorders that cannot be defected by karyotyping alone.8,12,13

For more information, please visit www.agilent.com/chem/contactus.
 

INTENDED USE: GenetiSure Dx Postnatal Assay is a qualitative assay intended for the postnatal detection of copy-number variations (CNV) and copy-neutral loss of heterozygosity (cnLOH) in genomic DNA obtained from peripheral whole blood in patients referred for chromosomal testing based on clinical presentation. GenetiSure Dx Postnatal Assay is intended for the detection of CNVs and cnLOH associated with developmental delay, intellectual disability, congenital anomalies or dysmorphic features. Assay results are intended to be used in conjunction with other clinical and diagnostic findings, consistent with professional standards of practice, including confirmation by alternative methods, parental evaluation, clinical genetic evaluation and counseling, as appropriate. Interpretation of assay results is intended to be performed only by healthcare professionals who are board-certified in clinical cytogenetics or molecular genetics.

The assay is intended to be used on the SureScan Dx Microarray Scanner System and analyzed by CytoDx Software.

WARNING: This device is not intended to be used for standalone or diagnostic purposes, pre-implantation or prenatal testing or screening, population screening or the detection of, or screening for, acquired or somatic genetic aberrations.

The products referenced on this page are not available for sale in all countries or jurisdictions. The information contained in this website may not be valid in your jurisdictions. Please contact your local sales representative for additional information.